93 research outputs found
Estudio de Prefactibilidad para la Producción local de autopartes plásticas en la empresa SISEC S.A. en el cantón Quito
El presente estudio consiste en la determinación de la factibilidad a priori de la producción local de autopartes plásticas en el Ecuador. Su objetivo radica en presentar información del sector automotriz y las condiciones de producción de las unidades automotrices ensambladas para el mercado local y de exportación, de las empresas Aymesa, Maresa y General Motors.
Para lograr lo anteriormente detallado, se recogió información de forma primaria, en reuniones con expertos del sector y, secundaria en documentación escrita y digital. El estudio consta de seis capítulos, en los que se desarrollan los diferentes ámbitos para determinar su viabilidad: información de la empresa, condiciones del proyecto e inversión extranjera en el sector automotriz; estudio de mercado; prefactbilidad técnica, ambiental y económico financiera; y presupuestación, niveles de inversión y financiamiento.The present study is to determine beforehand the feasibility of local production of plastic auto parts in Ecuador. Its aim is in present information of automotive sector and the production conditions of automotive units assembled for local and export markets, of companies Aymesa, Maresa and General Motors. To achieve the above detailed, the information was collected primarily, in meetings with industry experts and secondary, in print and digital documentation. The study consists on six chapters developed in different areas to determine its viability: company information, project conditions and foreign investment in automotive sector; market research; technical, environmental, economic and financial prefeasibility, and budgeting, investing and financing levels
Los Beneficios de las actividades de Ocio y Tiempo Libre en personas con enfermedad mental.
Iventigación centrada en descubrir los beneficios de las actividades de Ocio y Tiempo Libre en personas con enfermedad mental. El entorno donde se realiza la investigación se sitúa en la Fundación Rey Ardid
Granulocyte to monocyte ratio: leucokinetics in hematic biometry for appendicitis screening
Background: Acute appendicitis diagnosis is still challenging and is established with clinical history, physical exam, laboratory tests, and imaging studies. It´s crucial to analyze the blood biometry with physiopathological asses and not with a statistical approach for establishing diagnostic items. The interaction between neutrophils with monocytes is noticeable in the blood biometry, so its relationship could be explained as directly proportional to the neutrophils count because of cellular recruitment and inversely proportional to the monocyte count because of cellular migration.
Methods: A retrospective, transversal and analytic study was conducted, admission blood biometry of all patients (n=160) that went through appendectomy in Pemex´s North Central Hospital between 2014 and 2019 were dissected. Statistical correlation between sensibility and likelihood ratio of granulocyte/monocyte ratio (GMR), leucocyte elevation, and left shift of neutrophil count were contrasted. IBM® SPSS© statistical software performed the statistical analysis.
Results: GMR (1.00) sensitivity showed to be superior to leukocytosis (0.785) and percentage neutrophils (0.846). the same for the negative likelihood ratios (LR-) calculated for GMR (0.00), leukocytosis (0.59) and percentage of neutrophils (0.579).
Conclusions: GMR showed higher sensibility for detecting immune response in a patient with suspected acute appendicitis compared to leucocyte elevation and left shift of neutrophil count or both
Revisión bibliográfica: infección del sitio quirurgico
La infección del sitio quirúrgico es una de las infecciones asociada a la atencion medica más frecuentes, su incidencia se estima es de alrededor del 2-11 % para todas las intervenciones quirúrgicas. Se asocia con mayores costos de tratamiento, conducen a resultados adversos para el paciente incluida la estancia hospitalaria prolongada. Las primeras medidas activas para disminuir la incidencian contra las infecciones asociadas a la cirugia deben ser abordadas en todos los aspectos, tomando en cuenta los riesgos preoperatorios, intraoperatorios y posoperatorios en cada paso del proceso perioperatorio
Home Garden as Socio-Environmental Sustainability Option
El artículo tiene como objetivo analizar la estrategia “huertas caseras” como opción de sostenibilidad socio-ambiental, tomando como referente contextual la expe-riencia de acciones solidarias de seguridad alimentaria con familias del Municipio de Tenza (Boyacá, Colombia). La metodología se aborda desde tres fases: 1) Diagnós-tica, orientada al reconocimiento de la comunidad inter-venida, a través de una ficha de caracterización sociodemográfica, ambiental y de seguridad alimentaria; 2) Diseño de un plan estratégico con acciones solidarias para la atención de las necesidades encontradas en el diagnóstico. 3) Implementación del plan propuesto en las comunidades objeto de estudio. Los resultados evidencian como el modelo de huerta casera y el aprovechamiento de residuos sólidos orgánicos, resultan opciones estratégicas pertinentes para generar en la comunidad una iniciativa de reflexión sobre la seguridad alimentaria y la sosteni-bilidad socioambiental. Se concluye de esta forma como al contar con una mejor oferta alimenticia para la población, se podrá garantizar una óptima ingesta de nutrientes, mejorando los niveles de bienestar y estado de salud en sus habitantesThe objective of this article is to analyze the "home gardens" strategy as an option for socio-environmental sustainability, taking as a contextual reference the ex-perience of food security solidarity actions with fami-lies in the Municipality of Tenza (Boyacá, Colombia). The methodology is approached from three phases: 1) Diagnosis, oriented to the recognition of the intervened community, through a sociodemographic, environmen-tal and food security characterization file; 2) Design of a strategic plan with solidary actions for the attention of the needs found in the diagnosis. 3) Implementation of the proposed plan in the communities under study. The results show how the home-garden model and the use of solid organic waste are relevant strategic op-tions to generate in the community an initiative for reflection on food security and socioenvironmental sustainability. It is concluded in this way that by hav-ing a better food supply for the population, it will be possible to guarantee an optimal intake of nutrients, improving the levels of welfare and health status of its inhabitants
Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer
Background: Recent studies showed a relevant role of hematogenous spread in ovarian cancer and the interest of circulating tumor cells (CTCs) monitoring as a prognosis marker. The aim of the present study was the characterization of CTCs from ovarian cancer patients, paying special attention to cell plasticity characteristics to better understand the biology of these cells. Methods: CTCs isolation was carried out in 38 patients with advanced high-grade serous ovarian cancer using in parallel CellSearch and an alternative EpCAM-based immunoisolation followed by RT-qPCR analysis to characterize these cells. Results: Epithelial CTCs were found in 21% of patients, being their presence higher in patients with extraperitoneal metastasis. Importantly, this population was characterized by the expression of epithelial markers as MUC1 and CK19, but also by genes associated with mesenchymal and more malignant features as TIMP1, CXCR4 and the stem markers CD24 and CD44. In addition, we evidenced the relevance of TIMP1 expression to promote tumor proliferation, suggesting its interest as a therapeutic target. Conclusions: Overall, we evidenced the utility of the molecular characterization of EpCAM+ CTCs from advanced ovarian cancer patients to identify biomarkers with potential applicability for disseminated disease detection and as therapeutic targets such as TIMP1Part of this research was supported by CIBERONC funds (CB16/12/00328)S
Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas
Basal-like breast carcinoma is characterized by the expression of basal/
myoepithelial markers, undifferentiated phenotype, highly aggressive behaviour
and frequent triple negative status (ESR , PR , Her2neu ). We have previously
shown that epithelial–mesenchymal transition (EMT) occurs in basal-like breast
tumours and identified Lysyl-oxidase-like 2 (LOXL2) as an EMT player and poor
prognosis marker in squamous cell carcinomas. We now show that LOXL2 mRNA is
overexpressed in basal-like human breast carcinomas. Breast carcinoma cell lines
with basal-like phenotype show a specific cytoplasmic/perinuclear LOXL2 expression,
and this subcellular distribution is significantly associated with distant
metastatic incidence in basal-like breast carcinomas. LOXL2 silencing in
basal-like carcinoma cells induces a mesenchymal-epithelial transition (MET)
associated with a decrease of tumourigenicity and suppression of metastatic
potential. Mechanistic studies indicate that LOXL2 maintains the mesenchymal
phenotype of basal-like carcinoma cells by a novel mechanism involving transcriptional
downregulation of Lgl2 and claudin1 and disorganization of cell
polarity and tight junction complexes. Therefore, intracellular LOXL2 is a new
candidate marker of basal-like carcinomas and a target to block metastatic
dissemination of this aggressive breast tumour subtypeThis work was supported by
grants from the Spanish Ministry of Science and Innovation,
MICINN, (SAF2007-53061; SAF2010-21143; Consolider Ingenio
CSD2007/00017, to AC; SAF2007-63075; SAF2010-20175 to
GM-B); Fundacion Mutua Madrileña (2007, 2009 to AC and
GM-B); Instituto de Salud Carlos III (ISCIII) (PI 080971 to JP),
and Junta de Andalucıa (PI-0384/2007; PI 080971, P07-CVI-
03100 to JP). FS and A Martı´n are recipients of JAE-pre and
JAE-postdoc contracts from the Spanish Research Council
(CSIC), respectively; MAC is founded by the RETICS (ISCIII)
A general reaction mechanism for carbapenem hydrolysis by mononuclear and binuclear metallo-β-lactamases
Carbapenem-resistant Enterobacteriaceae threaten human health, since carbapenems are last resort drugs for infections by such organisms. Metallo-β-lactamases (MβLs) are the main mechanism of resistance against carbapenems. Clinically approved inhibitors of MBLs are currently unavailable as design has been limited by the incomplete knowledge of their mechanism. Here, we report a biochemical and biophysical study of carbapenem hydrolysis by the B1 enzymes NDM-1 and BcII in the bi-Zn(II) form, the mono-Zn(II) B2 Sfh-I and the mono-Zn(II) B3 GOB-18. These MβLs hydrolyse carbapenems via a similar mechanism, with accumulation of the same anionic intermediates. We characterize the Michaelis complex formed by mono-Zn(II) enzymes, and we identify all intermediate species, enabling us to propose a chemical mechanism for mono and binuclear MβLs. This common mechanism open avenues for rationally designed inhibitors of all MβLs, notwithstanding the profound differences between these enzymes' active site structure, β-lactam specificity and metal content.Fil: Lisa, María Natalia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; Argentina. Instituto Pasteur de Montevideo; UruguayFil: Palacios, Antonela Rocio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Aitha, Mahesh. Miami University; Estados UnidosFil: Gonzalez, Mariano Martin. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Moreno, Diego Martin. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Crowder, Michael W.. Miami University; Estados UnidosFil: Bonomo, Robert A.. Case Western Reserve University; Estados Unidos. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados UnidosFil: Spencer, James. University Walk; Reino Unido. University of Bristol; Reino UnidoFil: Tierney, David L.. Miami University; Estados UnidosFil: Llarrull, Leticia Irene. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Departamento de Química Biológica. Área Biofísica; ArgentinaFil: Vila, Alejandro Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Departamento de Química Biológica. Área Biofísica; Argentina. Case Western Reserve University; Estados Unido
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Altres ajuts: This work has been supported by the Community of Madrid (grant S2010/BMD-2303 to GMB), the Breast Cancer Research Foundation (BCRF) to JA. Alba Mota is a predoctoral student supported by a FPU fellowship (Spanish Ministry of Education, Culture and Sport). David Sarrio is a postdoctoral researcher funded by the AECC Scientific Foundation.Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant role in this cancer subtype. Here, using an in silico analysis of data from 2,096 breast tumours, we reveal a significant correlation between Gasdermin B (GSDMB) gene (located 175 kilo bases distal from ERBB2) expression and the pathological and clinical parameters of poor prognosis in HER2-positive breast cancer. Next, the analysis of three independent cohorts (totalizing 286 tumours) showed that approximately 65% of the HER2-positive cases have GSDMB gene amplification and protein over-expression. Moreover, GSDMB expression was also linked to poor therapeutic responses in terms of lower relapse free survival and pathologic complete response as well as positive lymph node status and the development of distant metastasis under neoadjuvant and adjuvant treatment settings, respectively. Importantly, GSDMB expression promotes survival to trastuzumab in different HER2-positive breast carcinoma cells, and is associated with trastuzumab resistance phenotype in vivo in Patient Derived Xenografts. In summary, our data identifies the ERBB2 co-amplified and co-expressed gene GSDMB as a critical determinant of poor prognosis and therapeutic response in HER2-positive breast cancer
Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19.
BACKGROUND
Prior studies of therapeutic-dose anticoagulation in patients with COVID-19 have reported conflicting results.
OBJECTIVES
We sought to determine the safety and effectiveness of therapeutic-dose anticoagulation in noncritically ill patients with COVID-19.
METHODS
Patients hospitalized with COVID-19 not requiring intensive care unit treatment were randomized to prophylactic-dose enoxaparin, therapeutic-dose enoxaparin, or therapeutic-dose apixaban. The primary outcome was the 30-day composite of all-cause mortality, requirement for intensive care unit-level of care, systemic thromboembolism, or ischemic stroke assessed in the combined therapeutic-dose groups compared with the prophylactic-dose group.
RESULTS
Between August 26, 2020, and September 19, 2022, 3,398 noncritically ill patients hospitalized with COVID-19 were randomized to prophylactic-dose enoxaparin (n = 1,141), therapeutic-dose enoxaparin (n = 1,136), or therapeutic-dose apixaban (n = 1,121) at 76 centers in 10 countries. The 30-day primary outcome occurred in 13.2% of patients in the prophylactic-dose group and 11.3% of patients in the combined therapeutic-dose groups (HR: 0.85; 95% CI: 0.69-1.04; P = 0.11). All-cause mortality occurred in 7.0% of patients treated with prophylactic-dose enoxaparin and 4.9% of patients treated with therapeutic-dose anticoagulation (HR: 0.70; 95% CI: 0.52-0.93; P = 0.01), and intubation was required in 8.4% vs 6.4% of patients, respectively (HR: 0.75; 95% CI: 0.58-0.98; P = 0.03). Results were similar in the 2 therapeutic-dose groups, and major bleeding in all 3 groups was infrequent.
CONCLUSIONS
Among noncritically ill patients hospitalized with COVID-19, the 30-day primary composite outcome was not significantly reduced with therapeutic-dose anticoagulation compared with prophylactic-dose anticoagulation. However, fewer patients who were treated with therapeutic-dose anticoagulation required intubation and fewer died (FREEDOM COVID [FREEDOM COVID Anticoagulation Strategy]; NCT04512079).Dr Stone has received speaker honoraria from Medtronic, Pulnovo,
Infraredx, Abiomed, and Abbott; has served as a consultant to
Daiichi-Sankyo, Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Ancora, Elucid Bio, Occlutech,
CorFlow, Apollo Therapeutics, Impulse Dynamics, Cardiomech, Gore,
Amgen, Adona Medical, and Millennia Biopharma; and has equity/
options from Ancora, Cagent, Applied Therapeutics, Biostar family of
funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix,
and Xenter; his daughter is an employee at IQVIA; and his employer,
Mount Sinai Hospital, receives research support from Abbott,
Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, BiosenseWebster, Shockwave, Vascular Dynamics, Pulnovo, and V-wave. Dr
Farkouh has received institutional research grants from Amgen,
AstraZeneca, Novo Nordisk, and Novartis; has received consulting
fees from Otitopic; and has received honoraria from Novo Nordisk. Dr
Lala has received consulting fees from Merck and Bioventrix; has
received honoraria from Zoll Medical and Novartis; has served on an
advisory board for Sequana Medical; and is the Deputy Editor for the
Journal of Cardiac Failure. Dr Moreno has received honoraria from
Amgen, Cuquerela Medical, and Gafney; has received payment for
expert testimony from Koskoff, Koskoff & Dominus, Dallas W. Hartman, and Riscassi & Davis PC; and has stock options in Provisio. Dr
Goodman has received institutional research grants from Bristol
Myers Squibb/Pfizer Alliance, Bayer, and Boehringer Ingelheim; has
received consulting fees from Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL
Behring, Ferring Pharmaceuticals, HLS Therapeutics, Novartis, Pendopharm/Pharmascience, Pfizer, Regeneron, and Sanofi; has received
honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim,
Bristol Myers Squibb, Eli Lilly, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, and Servier; has served on Data
Safety and Monitoring boards for Daiichi-Sankyo/American Regent
and Novo Nordisk A/C; has served on advisory boards for Amgen,
AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL
Behring, Eli Lilly, Ferring Pharmaceuticals, HLS Therapeutics, JAMP
Pharma, Merck, Novartis, Pendopharm/Pharmascience, Pfizer,
Regeneron, Sanofi, Servier, and Tolmar Pharmaceuticals; has a leadership role in the Novartis Council for Heart Health (unpaid); and
otherwise has received salary support or honoraria from the Heart
and Stroke Foundation of Ontario/University of Toronto (Polo) Chair,
Canadian Heart Failure Society, Canadian Heart Research Centre and
MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating
Centre for Clinical Research, Duke Clinical Research Institute, New
York University Clinical Coordinating Centre, PERFUSE Research
Institute, and the TIMI Study Group (Brigham Health). Dr Ricalde has
received consulting fees from Medtronic, Servier, and Boston Scientific; has received honoraria from Medtronic, Pfizer, Merck, Boston
Scientific, Biosensors, and Bayer; has served on an advisory board for
Medtronic; and has leadership roles in SOLACI and Kardiologen. Dr
Payro has received consulting fees from Bayer Mexico; has received
honoraria from Bayer, Merck, AstraZeneca, Medtronic, and Viatris;
has received payments for expert testimony from Bayer; has received
travel support from AstraZeneca; has served on an advisory board for
Bayer; and his institution has received equipment donated from
AstraZeneca. Dr Castellano has received consulting fees and honoraria from Ferrer International, Servier, and Daiichi-Sankyo; and has
received travel support from Ferrer International. Dr Hung has served
as an advisory board member for Pfizer, Merck, AstraZeneca, Fosun,
and Gilead. Dr Nadkarni has received consulting fees from Renalytix,
Variant Bio, Qiming Capital, Menarini Health, Daiichi-Sankyo, BioVie,
and Cambridge Health; has received honoraria from Daiichi-Sankyo
and Menarini Health; has patents for automatic disease diagnoses
using longitudinal medical record data, methods, and apparatus for
diagnosis of progressive kidney function decline using a machine
learning model, electronic phenotyping technique for diagnosing
chronic kidney disease, deep learning to identify biventricular
structure and function, fusion models for identification of pulmonary
embolism, and SparTeN: a novel spatio-temporal deep learning
model; has served on a Data Safety and Monitoring Board for CRIC
OSMB; has leadership roles for Renalytix scientific advisory board,
Pensive Health scientific advisory board, and ASN Augmented Intelligence and Digital Health Committee; has ownership interests in
Renalytix, Data2Wisdom LLC, Verici Dx, Nexus I Connect, and Pensieve Health; and his institution receives royalties from Renalytix. Dr
Goday has received the Frederick Banting and Charles Best Canada
Graduate Scholarship (Doctoral Research Award) from the Canadian
Institutes of Health Research. Dr Furtado has received institutional
research grants from AstraZeneca, CytoDin, Pfizer, Servier, Amgen,
Alliar Diagnostics, and the Brazilian Ministry of Health; has received
consulting fees from Biomm and Bayer; has received honoraria from
AstraZeneca, Bayer, Servier, and Pfizer; and has received travel support from Servier, AstraZeneca, and Bayer. Dr Granada has received
consulting fees, travel support, and stock from Cogent Technologies
Corp; and has received stock from Kutai. Dr Contreras has served as a
consultant for Merck, CVRx, Novodisk, and Boehringer Ingelheim;
and has received educational grants from Alnylam Pharmaceuticals
and AstraZeneca. Dr Bhatt has received research funding from Abbott,
Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen,
AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific,
Bristol Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi,
Cincor, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring
Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly,
Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo
Nordisk, Owkin, Pfizer Inc, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The
Medicines Company, Youngene, and 89bio; has received royalties
from Elsevier; has received consultant fees from Broadview Ventures
and McKinsey; has received honoraria from the American College of
Cardiology, Baim Institute for Clinical Research, Belvoir Publications,
Boston Scientific, Cleveland Clinic, Duke Clinical Research Institute,
Mayo Clinic, Mount Sinai School of Medicine, Novartis, Population
Health Research Institute, Rutgers University, Canadian Medical and
Surgical Knowledge Translation Research Group, Cowen and Company, HMP Global, Journal of the American College of Cardiology, K2P,
Level Ex, Medtelligence/ReachMD, MJH Life Sciences, Oakstone CME,
Piper Sandler, Population Health Research Institute, Slack Publications, WebMD, Wiley, Society of Cardiovascular Patient Care; has
received fees from expert testimony from the Arnold and Porter law
firm; has received travel support from the American College of Cardiology, Society of Cardiovascular Patient Care, American Heart Association; has a patent for otagliflozin assigned to Brigham and
Women’s Hospital who assigned to Lexicon; has participated on a
data safety monitoring board or advisory board for Acesion Pharma,
Assistance Publique-Hôpitaux de Paris, AngioWave, Baim Institute,
Bayer, Boehringer Ingelheim, Boston Scientific, Cardax, CellProthera,
Cereno Scientific, Cleveland Clinic, Contego Medical, Duke Clinical
Research Institute, Elsevier Practice Update Cardiology, Janssen,
Level Ex, Mayo Clinic, Medscape Cardiology, Merck, Mount Sinai
School of Medicine, MyoKardia, NirvaMed, Novartis, Novo Nordisk,
PhaseBio, PLx Pharma, Regado Biosciences, Population Health
Research Institute, and Stasys; serves as a trustee or director for
American College of Cardiology, AngioWave, Boston VA Research
Institute, Bristol Myers Squibb, DRS.LINQ, High Enroll, Society of
Cardiovascular Patient Care, and TobeSoft; has ownership interests in
AngioWave, Bristol Myers Squibb, DRS.LINQ, and High Enroll; has
other interests in Clinical Cardiology, the NCDR-ACTION Registry
Steering Committee; has conducted unfunded research with FlowCo
and Takeda, Contego Medical, American Heart Association Quality
Oversight Committee, Inaugural Chair, VA CART Research and Publications Committee; and has been a site co-investigator for Abbott,
Biotronik, Boston Scientific, CSI, St Jude Medical (now Abbott),
Phillips SpectraWAVE, Svelte, and Vascular Solutions. Dr Fuster declares that he raised $7 million from patients for this study granted to
Mount Sinai Heart, unrelated to industry. All other authors have reported that they have no relationships relevant to the contents of this
paper to disclose.S
- …